October 19, 2023
The U.S. Department of Health and Human Services (HHS) announced on October 13 that HHS and Pfizer have reached an agreement that will transition Paxlovid, the COVID-19 therapeutic, to the commercial market.
Preparations for the transition will begin next month, but Paxlovid will remain available for ordering from HHS through December 15.
Individuals on Medicare and Medicaid will access free government-procured Paxlovid through a patient assistance program through the end of 2024. Individuals who are uninsured or underinsured will access free government-procured Paxlovid through a patient assistance program through the end of 2028.
Pfizer will operate a copay assistance program for those with private insurance through 2028. Pfizer has agreed to replenish any government-procured product that is about to expire with up-to-date product and has also agreed to provide HHS with a stockpile of 1 million treatment courses for future COVID-19 surges.
HHS is working on additional details, particularly about the patient assistance program. Pfizer has not yet announced cost details for Paxlovid, but there is media speculation that the cost will be several times the current government negotiated price of $530/course.
August 20, 2026
A physician and Olympian will give an inspirational address as part of this year's Empowering Physicians event on Friday, September 25, at the Minneapolis Institute of Art.
August 20, 2026
Minnesota received some disturbing news this week from the Centers for Disease Control and Prevention (CDC), as data shows that for the 2025-2026 school year, vaccination rates decreased and non-medical exemptions increased.
August 20, 2026
On August 11, a federal appellate court sided with the Texas Medical Association (TMA) argument that the way the No Surprises Act’s qualifying payment amount (QPA) is calculated has historically favored payers in arbitration.